Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:

‍

Gilead Sciences will launch a randomized and double-blinded phase 3 trial for non-hospitalized COVID-19 patients, testing the efficacy of an oral antiviral, and will “prioritize sites that can move quickly with clinical trial enrollment.” (Fierce Pharma)

The U.S. Food and Drug Administration has issued a Class I recall for certain masks made by Philips Respironics for BiPAP, and CPAP machines. Magnets in the recalled masks may affect other medical devices.

In consideration of inadequate case counts, and unreported at-home tests, Betsy Ladyzhets examines the state of COVID-19 tracking. (Atlantic)

The CNS Summit 2022 will be held on November 17–20, in Boca Raton, Florida. Created as "a community of innovators and industry leaders who are not afraid to challenge the status quo," CNS was founded in 2009 to advance clinical development, focused on collaboration and innovation. Team AG Mednet will be there!

‍

‍

Our Culture

“Dossiers and redaction are built within the Judi platform, which helps significantly with adjudication management—and the client collaborates on the process.”

‍      –Jess, Program Manager‍

‍‍

‍

‍

About Judi

Judi empowers and enhances the world's clinical trial ecosystems. Our cloud-based platform has 120,000 users across 168 countries. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 Type II certified collaboration platform.